Phase III trial of Bevacizumab and chemotherapy in relapsed/refractory MBC (AVF2119g) Inclusion criteria prior anthracycline and taxane treatment —one or two prior chemotherapy regimens for MBC or —relapse within 12 months of completing anthracycline- and taxane- containing adjuvant therapy ECOG PS 0 or 1 Exclusion criteria antitumour therapy within 21 days anticoagulation therapy CNS metastases (head CT or MRI required) Miller KD, et al.
{}